Loading…
Edgewise Therapeutics, Inc. is projected to rise to $55.89 by 2027, a +23% move from its current price of $45.41. EWTX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $43.77 | $45.44 | $47.17 | +0.06% |
| Jul 13 | $43.13 | $45.47 | $47.93 | +0.13% |
| Jul 14 | $42.65 | $45.50 | $48.53 | +0.19% |
| Jul 15 | $42.25 | $45.52 | $49.05 | +0.25% |
| Jul 16 | $41.91 | $45.55 | $49.52 | +0.31% |
| Jul 17 | $41.60 | $45.58 | $49.94 | +0.38% |
| Jul 18 | $41.32 | $45.61 | $50.34 | +0.44% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $41.32 | $45.61 | $50.34 | +0.44% |
| Week 2 | $39.84 | $45.81 | $52.68 | +0.88% |
| Week 3 | $38.78 | $46.01 | $54.60 | +1.33% |
| Week 4 | $37.94 | $46.22 | $56.31 | +1.78% |
| Week 5 | $37.23 | $46.42 | $57.89 | +2.23% |
| Week 6 | $36.61 | $46.63 | $59.38 | +2.68% |
| Week 7 | $36.07 | $46.83 | $60.81 | +3.13% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Edgewise Therapeutics, Inc. is a biopharmaceutical company that discovers, develops, and commercializes therapies for the treatment of muscle disorders.
Its lead product candidate, sevasemten, is an orally administered small molecule that is in Phase II clinical trials and is designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
The company also develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. Edgewise was incorporated in 2017 and is headquartered in Boulder, Colorado.
Edgewise Therapeutics, Inc. (symbol: EWTX) currently trades at $46.30 per share with a market capitalization of $4.98B and is ranked 1365.
The near-term forecast for 2026 is NEUTRAL, with an average price of $46.30, a minimum of $22.94, and a maximum of $63.99.
From 2027 onward, the forecast is BULLISH, with the average price rising through the years and a sustained bullish sentiment toward 2050, including a path that reaches $113.98 by 2030 and extends to higher levels later in the decade and into 2040 and 2050.
A major floor 41.0% below — a decisive break under it would weaken the trend.
The nearest floor, 27.5% below — buyers have tended to step in here.
The nearest ceiling, 6.5% above — a clean break opens room to run.
A major ceiling 27.0% above — clearing it would confirm fresh momentum.
Key EWTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of EWTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $44.66 | Buy | $44.89 | Buy |
| MA 10 | $42.50 | Buy | $43.07 | Buy |
| MA 20 | $39.69 | Buy | $40.73 | Buy |
| MA 50 | $36.34 | Buy | $37.29 | Buy |
| MA 100 | $33.67 | Buy | $34.04 | Buy |
| MA 200 | $27.89 | Buy | $29.75 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 64.93 | Neutral |
| Stoch RSI (14) | 44.31 | Neutral |
| CCI (20) | 114.26 | Buy |
| Williams %R (14) | -24.81 | Info |
| MACD (12,26,9) | 0.68 | Buy |
| ROC (12) | 16.95 | Buy |
| Bollinger %B (20,2) | 0.85 | Neutral |
| Stochastic %K (14) | 75.19 | Neutral |
| TRIX (15) | 0.80 | Buy |
| Awesome (5,34) | 6.95 | Buy |
| Ultimate (7,14,28) | 67.62 | Neutral |
| Momentum (10) | 3.72 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 47.92 | Sell |
| ADX (14) | 22.95 | Buy |
| ATR (14) | 1.49 | Info |
The 30-day technical picture is bullish, with RSI(14) at 70 and sentiment labeled BULLISH.
The asset trades above the SMA50 of $35.70 and above the SMA200 of $27.57, indicating a positive short-term trend.
Support is at $32.92 and resistance at $46.30, with the 30-day price range from $36.49 to $58.74. Annualized volatility is 70%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $22.94 | $45.41 | $62.49 | 0% | Neutral | |
| $42.98 | $55.89 | $77.74 | +23% | Bullish | |
| $42.01 | $56.85 | $82.96 | +25% | Bullish | |
| $57.47 | $80.40 | $121.77 | +77% | Bullish | |
| $74.89 | $107.92 | $168.60 | +138% | Bullish | |
| $79.30 | $117.42 | $188.46 | +159% | Bullish | |
| $90.23 | $137.08 | $225.36 | +202% | Bullish | |
| $93.14 | $144.96 | $243.53 | +219% | Bullish | |
| $95.29 | $151.79 | $260.11 | +234% | Bullish | |
| $106.38 | $173.28 | $302.44 | +282% | Bullish | |
| $161.63 | $292.05 | $550.10 | +543% | Bullish | |
| $357.05 | $778.96 | $1,636.49 | +16.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $22.94 | $45.41 | $53.97 | +0.00% |
| August 2026 | $38.21 | $45.56 | $56.11 | +0.33% |
| September 2026 | $39.95 | $48.09 | $60.11 | +5.55% |
| October 2026 | $39.92 | $48.47 | $61.34 | +0.78% |
| November 2026 | $38.79 | $47.43 | $60.65 | -2.15% |
| December 2026 | $39.33 | $48.40 | $62.49 | +2.06% |
Click any year to see its month-by-month EWTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect EWTX to range from $22.94 to $62.49 through 2026. The $45.41 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The EWTX price prediction for 2027 points to an average of $55.89 (low $42.98, high $77.74) — a potential gain of +23% on today's $45.41. Momentum favours further upside here.
In 2028, EWTX is projected to trade between $42.01 and $82.96, averaging $56.85 — a potential gain of +25% from today's $45.41. That is up +2% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Edgewise Therapeutics, Inc.'s 2029 outlook centres on $80.40, within a $57.47 to $121.77 range. That is up +41% on the projected 2028 average. That marks a +77% change versus current levels. Momentum favours further upside here.
By 2030, EWTX could reach as high as $168.60, with a base case around $107.92 and support toward $74.89 — roughly +138% from $45.41. Buyers look set to stay in control over this stretch.
Expect EWTX to range from $79.30 to $188.46 through 2031. The $117.42 average target implies a +159% move from current prices. That is up +9% on the projected 2030 average. Momentum favours further upside here.
The EWTX price prediction for 2032 points to an average of $137.08 (low $90.23, high $225.36) — a potential gain of +202% on today's $45.41. Buyers look set to stay in control over this stretch.
In 2033, EWTX is projected to trade between $93.14 and $243.53, averaging $144.96 — a potential gain of +219% from today's $45.41. That is up +6% on the projected 2032 average. Momentum favours further upside here.
Edgewise Therapeutics, Inc.'s 2034 outlook centres on $151.79, within a $95.29 to $260.11 range. That is up +5% on the projected 2033 average. That marks a +234% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, EWTX could reach as high as $302.44, with a base case around $173.28 and support toward $106.38 — roughly +282% from $45.41. Momentum favours further upside here.
Expect EWTX to range from $161.63 to $550.10 through 2040. The $292.05 average target implies a +543% move from current prices. That is up +69% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The EWTX price prediction for 2050 points to an average of $778.96 (low $357.05, high $1,636.49) — a potential gain of +16.2x on today's $45.41. Momentum favours further upside here.
Investing $1,000 in EWTX today (≈ 22.021581 EWTX) could be worth
$17,153.9
+$16,153.9 (+1615%) by 2050 · US Dollar
Based on the average projected EWTX price of $778.96 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in EWTXwould be worth at today's price.
$1,000 invested in EWTX on Jul 10, 2025 (≈ 72.098054 EWTX) would be worth
$3,273.97
+$2,273.97 (+227.4%) today · 3.27× · US Dollar
Based on a EWTX entry price of $13.87 vs. today's $45.41.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $39.56 | $1,147.88 | +14.8% |
| 1 month ago | $32.92 | $1,379.4 | +37.9% |
| 3 months ago | $32.82 | $1,383.61 | +38.4% |
| 6 months ago | $24.13 | $1,881.89 | +88.2% |
| 1 year ago | $13.87 | $3,273.97 | +227.4% |
| All time (5.0y) ago | $24.1 | $1,884.23 | +88.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our EWTX forecast.
Our base-case forecast reaches $91.00 around 2030.
Implied market cap at $91.00: $9.79B
The multi-year forecast shows continued upside with a bullish sentiment through 2050. By 2030, the average forecast price is $113.98, representing a 146.2% ROI. The 2040 projection indicates an average of $318.90 with a 588.8% ROI, and by 2050 the average is $858.69 with a 1,754.6% ROI.
These figures suggest substantial appreciation potential over the long horizon, though they are estimates and not guarantees. Investors should consider the inherent uncertainty and the possibility of downside risk as market conditions evolve.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $113.98, a min of $79.74, and a max of $176.61, with a 146.2% ROI and bullish sentiment.
Forecasts indicate bullish sentiment from 2027 onward, with rising averages: $57.75 in 2027, $59.71 in 2028, $85.34 in 2029, $113.98 in 2030, and up to $858.69 in 2050, though these are estimates and not guarantees.
Yes. The forecast maximum by 2050 is $1,777.78, indicating potential to surpass $1,000.
Current price is $46.30 and market cap is $4.98B.
The 30-day range is $36.49 to $58.74.
Edgewise Therapeutics, Inc. Community Discussion
0Share your Edgewise Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.